ThinkEquity Downgrades Par Pharmaceutical (PRX) to Hold
Tweet Send to a FriendGet Alerts PRX Hot Sheet
Price: $49.98 --0%
Rating Summary:
2 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
2 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade PRX Now!
ThinkEquity downgraded Par Pharmaceutical (NYSE: PRX) from Buy to Hold with a price target of $50.00. The downgrade comes after this week's buyout deal.
For an analyst ratings summary and ratings history on Par Pharmaceutical click here. For more ratings news on Par Pharmaceutical click here.
Shares of Par Pharmaceutical closed at $50.05 yesterday, with a 52 week range of $24.85-$52.33.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on Par Pharmaceutical click here. For more ratings news on Par Pharmaceutical click here.
Shares of Par Pharmaceutical closed at $50.05 yesterday, with a 52 week range of $24.85-$52.33.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Goldman Sachs Downgrades Palo Alto Networks (PANW) to Buy
- Susquehanna Downgrades Red Hat (RHT) to Neutral
- UPDATE: Canaccord Genuity Starts T-Mobile US, (TMUS) at Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
ThinkEquity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
